- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07580248
Effects of Supplementation on Performance in Football Players (FOOTBALL-TCP)
Effects of Combined Taurine, Caffeine, and Phosphatidylserine Supplementation on Physical and Cognitive Performance in Professional Male Football Players
This study investigated the effects of short-term supplementation with taurine, caffeine, and phosphatidylserine on physical and cognitive performance in professional male football players. Eighty-one players were randomly assigned to one of three groups: placebo, taurine plus caffeine, or taurine plus caffeine combined with phosphatidylserine. Supplementation was administered for 10 days, with a final dose taken 60 minutes before a standardized 105-minute football training session.
Primary and secondary outcomes included sprint performance, reaction time, GPS-derived locomotor variables, and technical and tactical performance indicators. The aim of the study was to evaluate whether combined multi-ingredient supplementation could improve performance and attenuate fatigue-related declines under match-like conditions.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This randomized, placebo-controlled, single-blind study evaluated the effects of combined supplementation with taurine, caffeine, and phosphatidylserine on physical and cognitive performance in professional male football players.
Eighty-one participants aged 19-32 years were randomly assigned to one of three groups: placebo (lactose), taurine plus caffeine (1500 mg taurine + 200 mg caffeine), or taurine plus caffeine plus phosphatidylserine (1500 mg taurine + 150 mg caffeine + 300 mg phosphatidylserine daily for 10 days). All participants completed a 10-day supplementation period, followed by a standardized 105-minute football training session.
Outcome measures included sprint performance (30 m sprint time), reaction time (visual and auditory), GPS-derived variables (total distance, sprint activity, speed, accelerations, and decelerations), and technical and tactical performance indicators assessed by coaching staff and video analysis.
The study was conducted under controlled environmental conditions and in accordance with standardized training procedures. Data were analyzed using analysis of variance (ANOVA) with post hoc testing. The aim was to determine whether multi-ingredient supplementation could enhance performance and reduce fatigue-related declines in a football-specific setting.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Łódżkie
-
Lodz, Łódżkie, Polen, 94-020
- ŁKS Łódź
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Male professional football (soccer) players
- Age 19-32 years
- Currently participating in regular team training (4-5 sessions per week)
- Medically cleared for participation in high-intensity physical activity
- Provided written informed consent
Exclusion Criteria:
- Current injury or musculoskeletal condition affecting performance
- Chronic disease or medical condition
- Use of medications that may affect physical or cognitive performance
- Regular use of dietary supplements or caffeine prior to the study period
- Smoking or alcohol consumption
- Failure to comply with study procedures
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
Participants received a placebo (lactose) daily for 10 days.
|
Placebo (lactose) administered daily for 10 days
|
|
Eksperimentel: Taurine + Caffeine
Participants received taurine (1500 mg) and caffeine (200 mg) daily for 10 days.
|
Taurine 1500 mg and caffeine 200 mg administered daily for 10 days
|
|
Eksperimentel: Taurine + Caffeine + PS
Participants received taurine (1500 mg), caffeine (150 mg), and phosphatidylserine (300 mg) daily for 10 days.
|
Taurine 1500 mg, caffeine 150 mg, and phosphatidylserine 300 mg administered daily for 10 days
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
30 m sprint time (seconds)
Tidsramme: Day 10 (final training session following supplementation)
|
Time to complete a 30 meter sprint under standardized conditions, expressed in seconds; calculated as the mean of valid trials.
|
Day 10 (final training session following supplementation)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Reaction time (visual and auditory)
Tidsramme: Day 10 (post-supplementation)
|
Visual and auditory reaction time measured using standardized computerized reaction time tests (e.g., validated software-based assessment tools), expressed as mean response time in seconds across valid trials.
|
Day 10 (post-supplementation)
|
|
Total distance (meters)
Tidsramme: Day 10 (during standardized training session)
|
Total distance covered during the standardized training session, measured using GPS tracking devices (e.g., 10 Hz GPS units), expressed in meters.
|
Day 10 (during standardized training session)
|
|
Running speed (m/s)
Tidsramme: Day 10 (during standardized training session)
|
Mean running speed during the standardized training session, measured using GPS tracking devices (e.g., 10 Hz GPS units), expressed in meters per second.
|
Day 10 (during standardized training session)
|
|
Sprint count (number)
Tidsramme: Day 10 (during standardized training session)
|
Total number of sprint efforts recorded during the standardized training session using GPS tracking devices.
|
Day 10 (during standardized training session)
|
|
High-speed running distance (meters)
Tidsramme: Day 10 (during standardized training session)
|
Distance covered at high-speed running thresholds during the standardized training session, measured using GPS tracking and expressed in meters.
|
Day 10 (during standardized training session)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sprint time decline (%)
Tidsramme: Day 10 (during final training session; comparison between first and second halves)
|
Percentage decline in 30 m sprint time between the first and second halves of the standardized training session, measured using electronic timing gates and expressed as percentage change.
|
Day 10 (during final training session; comparison between first and second halves)
|
|
Running speed decline (%)
Tidsramme: Day 10 (during final training session; comparison between first and second halves)
|
Percentage decline in running speed between the first and second halves of the standardized training session, measured using GPS tracking devices and expressed as percentage change.
|
Day 10 (during final training session; comparison between first and second halves)
|
|
Passing accuracy (%)
Tidsramme: Day 10 (during standardized training session)
|
Percentage of successful passes during the standardized training session, assessed using video-based performance analysis and expressed as a percentage.
|
Day 10 (during standardized training session)
|
|
Dribbling success (%)
Tidsramme: Day 10 (during standardized training session)
|
Percentage of successful dribbling attempts during the standardized training session, assessed using video-based performance analysis and expressed as a percentage.
|
Day 10 (during standardized training session)
|
|
Ball recoveries (number)
Tidsramme: Day 10 (during standardized training session)
|
Total number of ball recoveries performed during the standardized training session, assessed using video-based performance analysis and expressed as a count.
|
Day 10 (during standardized training session)
|
|
Tactical performance score (units)
Tidsramme: Day 10 (during standardized training session)
|
Coach-rated tactical performance during the standardized training session, including positioning, decision-making, and support play, assessed using a standardized rating scale and expressed in standardized score units.
|
Day 10 (during standardized training session)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Krzysztof Maciej MIZERA, PhD, 1. Vizja University in Warsaw, Faculty of Medical Sciences and Health Sciences, 01-143 Warsaw, Poland
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Lipider
- Kulbrinter, acyklisk
- Kulbrinter
- Alkaloider
- Purinoner
- Puriner
- Alkaner
- Alkanesulfonsyrer
- Sulfonsyrer
- Svovlsyrer
- Membranlipider
- Xanthines
- Glycerophospholipider
- Phosphatidinsyrer
- Glycerophosphater
- Phospholipider
- Koffein
- Taurin
- Phosphatidylseriner
Andre undersøgelses-id-numre
- MIZERA-2025-FOOTBALL-RCT
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AkesoIkke rekrutterer endnuAtopisk dermatitisKina
-
CellmedisMedical Network Sp. z o.o.Ikke rekrutterer endnu
-
Texas A&M UniversityNutraboltAfsluttetGlukose og insulinrespons
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
LifeMine TherapeuticsRekruttering
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater